Non-fucosylated Anti-Human HER2 Therapeutic Antibody, an ADCC-Enhanced Biobetter [Lot: CB20-PZ07] (CAT#: BioBet-007ZP) Datasheet

Target
HER2
Isotype
Whole Humanized Antibody
Description
ADCC-enhanced Pertuzumab is a non-fucosylated anti-HER2 therapeutic biobetter antibody. Creative Biolabs' Afuco™ technology platform allows for the control of glycosylation level, thereby achieving ADCC-Enhanced Anti-HER2 Pertuzumab, a biobetter by reducing fucosylation of the Fc region of Pertuzumab, leading to an increased binding affinity for the FcyR receptor on immune effector cells.
More specifically, the afucosylated therapeutic biobetter antibody was generated by recombinant DNA technology. It has been produced in CHO cells that are deficient for fucosylation and purified by affinity chromatography with protein G. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC).
Indication
Early Breast Cancer
Inflammatory carcinoma of the breast
Locally Advanced Breast Cancer (LABC)
Metastatic Breast Cancer
Classification
Therapeutic antibody; biobetter
Patent
The patents on Herceptin will expire in the US in June 2019 and expired in Europe in July 2014.
Status
Preclinical

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Pertuzumab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
ERBB2
Full Name
erb-b2 receptor tyrosine kinase 2
Background
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
Alternative Names
NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu
Gene ID
UniProt ID
Cellular Localization
Plasma membrane, Endosome, Nucleus.
HGNC
OMIM
Involvement in Disease
Diseases associated with ERBB2 include Glioma Susceptibility 1 and Gastric Cancer.
Related Pathways
Its related pathways are Association Between Physico-Chemical Features and Toxicity Associated Pathways and RET signaling.
Function
1.Protein tyrosine kinases are part of several cell surface receptor complexes, but obviously require a co-receptor to which a ligand binds. An essential component of the neurotonin receptor complex, although neurotonin does not interact with it alone. GP30 is a potential ligand for this receptor. Regulate the growth and stability of peripheral microtubules (MTs). After ERBB2 is activated, the memo1-rhoa-991 signaling pathway triggers the phosphorylation of GSK3B on the cell membrane, thereby inhibiting GSK3B. This prevents the phosphorylation of APC and CLASP2, allowing them to bind to the cell membrane. In turn, membrane-bound APC allows MACF1 to localize to the cell membrane, which is necessary for microtubule capture and stabilization. 2.Participate in transcriptional regulation in the nucleus. It is associated with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Participate in CDKN1A transcriptional activation; functions include STAT3 and SRC. Participate in the transcription of rRNA genes through RNA Pol I, and promote protein synthesis and cell growth.
Field of research
Cancer antibody; Controls and Markers antibody; Signaling Transduction antibody; Circulating Tumor Cells BioMarker antibody
Post-translational modifications
Autophosphorylated. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit (Probable). Ligand-binding increases phosphorylation on tyrosine residues (PubMed:27134172). Signaling via SEMA4C promotes phosphorylation at Tyr-1248 (PubMed:17554007). Dephosphorylated by PTPN12 (PubMed:27134172).
Trade name
Perjeta
Groups
Approved
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
DB06366
CAS number
380610-27-5
Antibody Isotype
Whole Humanized Antibody
Antibody Clone
Pertuzumab
Description
Pertuzumab (also known as 2C4, trade name Perjeta) is a recombinant humanized monoclonal antibody that targets the extracellular domain of human epidermal growth factor receptor 2 protein (HER2). It was first approved by the FDA in 2012 for the treatment of metastatic HER2-positive breast cancer; in early HER2-positive breast cancer, it is also used in the same combination as a new adjuvant. It was originally discovered and developed by Roche's subsidiary Genentech.
Indication
Early Breast Cancer
Inflammatory carcinoma of the breast
Locally Advanced Breast Cancer (LABC)
Metastatic Breast Cancer
Synonyms
2C4 Antibody
MOAB 2C4
Monoclonal Antibody 2C4
Omnitarg
rhuMAb-2C4
UNII
K16AIQ8CTM

Pertuzumab is a humanized monoclonal antibody designed to target the extracellular dimerization domain of Her2. At the same time, it can also inhibit the dimerization of other HER family members (HER1, HER2, HER3 and HER4) on the surface of cancer cells. In addition, Pertuzumab also inhibits downstream activation of the PI3K and MAPK pathways. Like trastuzumab, pertuzumab also stimulates antibody-dependent cell-mediated cytotoxicity (ADCC).

Pertuzumab can be used in combination with trastuzumab and docetaxel to treat patients with HER2-positive metastatic breast cancer who have not received anti-HER2 treatment or chemotherapy for metastatic disease.

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK